(MYGN) Myriad Genetics, Inc. Company Overview

Myriad Genetics, Inc. is a molecular diagnostics and precision-medicine company listed on the Nasdaq Global Select Market under the ticker MYGN. Rather than selling drugs or medical devices, it sells laboratory tests that translate genetic, genomic, and molecular signals into information used to assess inherited disease risk, select therapies, estimate disease progression, and guide reproductive or psychiatric care. The company reports one operating segment, but management organizes its commercial portfolio into three practical product groups: Cancer Care Continuum, Prenatal Health, and Mental Health.

The company's stated mission is to advance health and well-being by revealing actionable biological information. That positioning is not merely branding: diagnostics create value only when a physician trusts the analytical result, a payer accepts the clinical utility, and the test changes a real care decision. Myriad's official company profile emphasizes more than three decades in genetic testing and a broad clinical evidence base.

Which clinical decisions does the portfolio support?

Myriad earns most revenue when a completed test is billable to a commercial insurer, Medicare, another government program, a healthcare institution, or a self-paying patient. The revenue equation is therefore approximately test volume multiplied by average revenue per test, adjusted for payer mix, coverage policy, contracted pricing, denials, collections, and revenue-estimate changes. This is unlike a subscription software model: an order is not fully valuable until the specimen is processed, the report is delivered, and reimbursement is collectible.

Which revenue source was largest in FY2025?

The FY2025 Form 10-K shows $824.5 million of total revenue. Hereditary Cancer generated $372.4 million, or about 45.2% of the total, making it the largest disclosed product category. Prenatal contributed $186.3 million, Mental Health $144.1 million, and Tumor Profiling $121.7 million. Those four categories are the annual-report presentation; beginning in 2026, management grouped hereditary cancer and tumor profiling with newer oncology offerings inside Cancer Care Continuum.

Revenue is overwhelmingly concentrated in the United States. This simplifies the commercial model but makes U.S. reimbursement policy, coding decisions, and payer contracting unusually important.

Myriad's current strategic center is oncology. Management is trying to connect inherited-risk testing, companion diagnostics, tumor profiling, prostate prognosis, and longitudinal molecular residual disease testing into a broader Cancer Care Continuum. The strategic benefit is potential lifetime value: one health system or oncology practice could use multiple Myriad tests at different stages of a patient's care. The execution challenge is that each application needs evidence, workflow integration, sales specialization, and payer acceptance.

Cancer Care Continuum: the growth engine

Cancer Care Continuum revenue and volume both increased year over year, but volume grew faster than revenue, signaling the importance of mix and realized reimbursement. Newer products could expand the addressable market: Myriad launched Precise MRD in March 2026, and in June broadened availability to breast, colorectal, and renal cancers. The June 2026 Precise MRD update says the whole-genome assay can track up to 1,000 patient-specific variants.

Prenatal and Mental Health: contrasting economics

FirstGene is intended to combine several prenatal screens into one workflow. Its February 2026 analytical validation announcement is scientifically encouraging, but commercial value will depend on clinical study completion, physician adoption, reimbursement, and whether the combined test simplifies rather than complicates prenatal practice.

The quarter ended March 31, 2026 showed modest top-line growth but continued GAAP losses and cash consumption. According to the Q1 2026 earnings release, revenue rose 2% to $200.4 million. Total test volume was flat at 385,000, while average revenue per test improved. This means reported growth came primarily from realized price and mix rather than aggregate volume expansion.

Why does the gross margin matter?

Management reiterated FY2026 guidance of $860 million to $880 million in revenue, 68% to 69% adjusted gross margin, and $37 million to $49 million of adjusted EBITDA, with second-half revenue expected to exceed first-half revenue. The latest Form 10-Q also shows $124.4 million of cash and $120.3 million of long-term debt at March 31, 2026. The practical question is whether product launches and prenatal recovery can improve revenue faster than the cost base expands.

Myriad's history explains both its credibility and its current strategic tension. It helped pioneer commercial hereditary cancer testing, then broadened through acquisitions into mental health and reproductive genetics. The business now has more diversified clinical reach, but it also carries acquired intangible assets, multiple commercial workflows, reimbursement complexity, and the need to prove that newer platforms can generate durable returns.

1. 1990s
   BRCA-era foundation. Myriad's work around BRCA1 and BRCA2 established its hereditary-cancer identity, evidence culture, and physician relationships.
2. 2013
   Patent model reset. The U.S. Supreme Court's decision in Association for Molecular Pathology v. Myriad Genetics changed the intellectual-property landscape for naturally occurring DNA, increasing the importance of databases, evidence, service, and product execution rather than gene exclusivity alone.
3. 2016
   GeneSight added. Myriad completed the Assurex Health acquisition, bringing pharmacogenomic testing into mental health and creating a distinct reimbursement-sensitive growth business.
4. 2018
   Prenatal scale expanded. The Counsyl acquisition added carrier screening and noninvasive prenatal testing, broadening Myriad beyond oncology.
5. 2022
   Consumer-access layer. Gateway Genomics and SneakPeek added an early-pregnancy consumer channel that complements clinician-ordered reproductive testing.
6. 2024-25
   Portfolio and leadership reset. Myriad divested its European EndoPredict business, partnered with PATHOMIQ for AI-enabled prostate pathology, and appointed Samraat Raha chief executive in April 2025.
7. 2026
   Cancer continuum expansion. Precise MRD launched, MyChoice CDx received additional regulatory approvals, and Prolaris incorporated AI-enabled digital pathology—raising the potential value of Myriad's oncology sales channel.

The 2016 Assurex transaction and 2018 Counsyl transaction explain why the company now spans three clinical markets. They also explain part of the balance-sheet burden: acquired goodwill and intangible assets are subject to impairment when expected cash flows weaken. FY2025's $319.4 million of goodwill and long-lived asset impairment charges was therefore not a random accounting event; it reflected reduced expectations for parts of the acquired portfolio.

Myriad does not have a single, impregnable moat. Its defensibility is cumulative: clinical evidence, laboratory quality, physician relationships, payer contracts, brand recognition, proprietary algorithms, data accumulated across tests, and the operational ability to process and bill high test volumes. These assets can create switching costs because a health system must evaluate analytical performance, clinical utility, ordering workflow, patient support, and reimbursement before changing vendors.

Why is evidence a strategic asset?

A molecular test is more defensible when it can demonstrate analytical validity, clinical validity, and clinical utility. That evidence supports guidelines, physician confidence, payer coverage, and regulatory submissions. Precise MRD illustrates the model: a pan-cancer analysis reported 97% baseline detection, while a later breast-cancer study evaluated 154 patients. These data do not guarantee reimbursement or adoption, but they strengthen the case that the assay can influence surveillance and treatment decisions.

Where is the moat weakest?

Reimbursement remains the weakest link because insurers can narrow coverage, lower payment, require prior authorization, or favor alternatives. Myriad also competes against laboratories with larger testing menus, oncology specialists with deep sequencing platforms, and newer companies using liquid biopsy or artificial intelligence. The result is a moat that must be continually renewed through evidence, product performance, contracting, and sales execution.

Competition varies by clinical market. Large reference laboratories can bundle testing with broad logistics and payer relationships; specialist diagnostics firms may lead in a narrow tumor type or technology; and sequencing-focused companies can invest aggressively in liquid biopsy, data, and software. Myriad's FY2025 filing names Natera, Foundation Medicine, Caris Life Sciences, Tempus AI, Labcorp, Quest Diagnostics, Veracyte, Guardant Health, MDxHealth, NeoGenomics, BillionToOne, Fulgent Genetics, and Genomind among relevant rivals.

How should students frame the industry structure?

Porter's Five Forces logic is visible without forcing a template: rivalry is high, payers have substantial buyer power, technology creates substitution risk, evidence and regulatory requirements raise entry barriers, and suppliers of specialized instruments, reagents, data, and licensed intellectual property can affect costs. Myriad's answer is differentiation through clinically meaningful interpretation rather than competing solely on sequencing capacity.

Myriad has enough liquidity to operate and invest, but it is not yet financially strong in the conventional sense of sustained GAAP profits and positive free cash flow. FY2025 revenue declined 2% to $824.5 million. The company generated a 69.9% gross margin, but operating expenses were elevated and it recorded $319.4 million of impairment charges. The result was a large GAAP loss despite attractive laboratory-level economics.

What does the balance sheet permit?

How does cash convert after reinvestment?

The main capital-allocation priority is reinvestment rather than dividends or repurchases. Research, commercial spending, and administrative infrastructure collectively consume substantial resources. This shows the strategic trade-off: Myriad needs science and commercial reach to defend and expand its portfolio, but the combined expense base delays profitability. The term-loan facility provides financing capacity, yet debt is not a substitute for durable cash generation.

Myriad has a conventional common-equity structure rather than founder control through a dual-class arrangement. The investor base is institutionally influenced, while insiders own a relatively small economic stake. The 2026 proxy statement lists several holders with meaningful positions.

How are management incentives structured?

Annual incentives emphasized revenue and adjusted operating income, with smaller weights for employee engagement, net promoter score, and individual goals. Performance-share awards used revenue, adjusted EPS, and relative total shareholder return as long-term metrics. This design broadly aligns management with growth and profitability, although adjusted measures should always be reconciled to GAAP results. Samraat Raha became president and CEO in April 2025, making leadership execution and organizational stability important watch items.

Myriad's opportunity set is credible but execution-dependent. The strongest growth case is that its established hereditary-cancer franchise becomes the entry point for a broader oncology platform. Precise MRD can add repeat testing over time, MyChoice CDx can deepen pharmaceutical partnerships, and Prolaris plus AI can improve prostate-cancer differentiation. In Prenatal Health, FirstGene could simplify multiple screens, while Mental Health can grow if GeneSight reimbursement and physician confidence continue to improve.

Which risks could change the outlook?

The most concrete recent warning is reimbursement. The FY2025 filing says UnitedHealthcare's withdrawal of coverage for multi-gene pharmacogenomic testing, including GeneSight, harmed revenue, profitability, and cash flow and was expected to continue affecting results. This demonstrates why a clinically useful test can still be economically fragile when payer policy changes.

Which drivers matter in a DCF or comparable-company analysis?

For valuation, a single revenue multiple can obscure the story. Hereditary cancer is established, Precise MRD is an emerging platform, Prenatal Health is recovering from execution issues, and GeneSight carries reimbursement concentration. A useful model should therefore use scenario ranges for volume, realized payment, gross margin, operating-expense leverage, and cash conversion rather than extrapolating one consolidated growth rate.

Myriad matters because it combines a historically important hereditary-cancer franchise with a broader ambition to become a multi-stage precision-medicine platform. Its assets are real: decades of molecular-diagnostics experience, extensive clinical evidence, national physician reach, recognizable products, and a portfolio that spans inherited risk, therapy selection, prognosis, recurrence monitoring, prenatal screening, and pharmacogenomics.

The central tension is equally clear. The company produces attractive laboratory gross margins but has not yet converted them into consistent GAAP profit or free cash flow. Reimbursement decisions can overpower volume growth, acquired businesses have produced impairment charges, and emerging products require sustained evidence and commercial investment. Q1 2026 offered a mixed but useful signal: revenue and gross margin improved modestly, Cancer Care Continuum and GeneSight grew, Prenatal Health declined, and cash flow remained negative.